Clinical Trials In Australia For US MedTech Companies

Mobius supports US MedTech companies running clinical trials in Australia with clinical trial strategy, feasibility, HREC and CTN/CTA pathway coordination support, site activation, monitoring, data quality, sponsor oversight, and US-aligned evidence planning.

Talk to Mobius about Australia

Australian clinical trial support for US sponsors

Australia can be efficient and credible for the right MedTech study, but it is not automatically the right first choice. The value depends on the product, intended use, endpoints, site access, pathway assumptions, and how the evidence will be used later.

Fit

Assess whether Australia is suitable for the sponsor's evidence goal and operational constraints.

Pathway

Plan practical CTN, CTA, HREC, governance, document, and site start-up implications with adviser input where needed.

Execution

Support local sites, investigators, vendors, monitoring, and data quality while keeping US sponsor oversight visible.

When Australia may be a strong fit

US MedTech companies often consider Australia when the study needs experienced clinicians, focused site engagement, and a practical route into clinical evidence generation.

Early feasibility or first clinical experience. Generate real clinical use, procedural insight, safety information, usability feedback, or early performance evidence before a larger program.

First-in-human or early-stage device work. Use carefully controlled clinical investigation with sites and oversight suited to a new technology.

Pivotal or decision-supporting evidence. Build evidence where endpoints, population, data quality, and follow-up align with broader regulatory and commercial goals.

Regional execution for US sponsors. Work with Australian sites and vendors without building local infrastructure from scratch.

When Australia is not the right first choice

A credible Australia strategy includes knowing when not to use it. If the evidence needs to be generated directly in the US healthcare setting, if the target population is not accessible locally, if endpoints do not translate well, or if pathway assumptions have not been tested with advisers, Australia may add complexity without enough strategic value.

Mobius helps US sponsors decide whether Australia, the United States, New Zealand, or a multi-region approach best supports the next decision.

Explore US and Australia trial strategy

Trial pathway strategy ->

CTN, CTA, HREC, and local pathway considerations

Australian clinical trials are commonly conducted under the Clinical Trial Notification pathway or, in some cases, the Clinical Trial Approval pathway. Ethics review is handled through a Human Research Ethics Committee, and site governance requirements need to be planned alongside ethics and regulatory steps.

Mobius helps sponsors understand practical implications around study documents, investigator responsibilities, safety reporting, governance timelines, and local operating model. We do not replace specialist legal or regulatory advice.

View medical device CRO support in Australia

Explore regulatory-aware evidence planning

Regulatory planning ->

FDA-aware evidence planning for Australian studies

For US MedTech companies, the important question is whether the Australian study design and data package will be useful for the next decision. That may involve FDA discussions, investor diligence, board milestones, design iteration, reimbursement planning, commercial claims, or a later US study.

Foreign clinical data can be useful, but it needs to be scientifically credible, operationally defensible, and relevant to intended use and target population.

View medical device CRO United States

US CRO support ->

Local execution for US sponsors

US sponsors running studies in Australia need active visibility across recruitment, activation, monitoring, safety reporting, data quality, open action items, and upcoming risks.

Mobius can work as the primary CRO for an Australian program, provide focused local support within a broader global study, or help US sponsors oversee Australian vendors and sites.

Explore clinical trial execution

Clinical trial execution ->

Relevant Mobius experience

Use our case studies to see how Mobius supports MedTech teams across feasibility, pivotal, AI, interventional, and patient-centred evidence programs.

AI-powered skin cancer detection

FIH

Mitral valve innovation from early feasibility to pivotal study

Pivotal

World-first aspiration thrombectomy trial

Patient

Non-invasive pain relief device for pregnancy

See case studies ->

Questions US sponsors ask about Australian trials

Short answers for US MedTech companies considering Australian clinical trial support.

Do US MedTech companies run clinical trials in Australia?

Yes. US MedTech companies may consider Australia for feasibility, first-in-human, pivotal, post-market, or multi-region clinical evidence programs. Whether Australia is appropriate depends on the product, intended use, study population, endpoints, site access, regulatory pathway, and how the data will be used.

What is the CTN pathway in Australia?

The Clinical Trial Notification pathway is commonly used for Australian clinical trials where the relevant requirements are met. The study still requires ethics review, site governance, appropriate documentation, safety processes, monitoring, and sponsor oversight. Sponsors should confirm pathway suitability with appropriate regulatory advisers.

Can Australian clinical trial data support a US MedTech evidence strategy?

Australian clinical trial data may be useful for US MedTech evidence planning when the study is designed and conducted in a way that is scientifically credible, operationally defensible, and relevant to the sponsor's intended use and target population.

Does Mobius support US-only studies as well as Australian studies?

Yes. Mobius supports Australian trials for US MedTech sponsors, US-only studies, and multi-region clinical programs across the United States, Australia, and New Zealand.

Can Mobius help with HREC and site governance coordination?

Yes. Mobius can support HREC and site governance coordination, study document preparation, site start-up tracking, vendor coordination, and practical operational planning for Australian studies.

Talk to Mobius ->

Talk to Mobius before you lock the Australia plan

Tell us what evidence you need, whether the study needs to support US or multi-region decisions, and what assumptions you are making about Australia.

Schedule A Call